Evaluation of Hyaluronic Acid to Modulate Oral Squamous Cell Carcinoma Growth in Vitro by Ringer, Jordan et al.
Dental Medicine Faculty Publications School of Dental Medicine 
10-1-2020 
Evaluation of Hyaluronic Acid to Modulate Oral Squamous Cell 
Carcinoma Growth in Vitro 
Jordan Ringer 
University of Nevada, Las Vegas 
Bryan Morrison 
University of Nevada, Las Vegas 
Karl Kingsley 
University of Nevada, Las Vegas, karl.kingsley@unlv.edu 
Follow this and additional works at: https://digitalscholarship.unlv.edu/dental_fac_articles 
 Part of the Biomaterials Commons 
Repository Citation 
Ringer, J., Morrison, B., Kingsley, K. (2020). Evaluation of Hyaluronic Acid to Modulate Oral Squamous Cell 
Carcinoma Growth in Vitro. Journal of Functional Biomaterials, 11(4), 1-11. 
http://dx.doi.org/10.3390/JFB11040072 
This Article is protected by copyright and/or related rights. It has been brought to you by Digital Scholarship@UNLV 
with permission from the rights-holder(s). You are free to use this Article in any way that is permitted by the 
copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from 
the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/
or on the work itself. 
 
This Article has been accepted for inclusion in Dental Medicine Faculty Publications by an authorized administrator 





Evaluation of Hyaluronic Acid to Modulate Oral
Squamous Cell Carcinoma Growth In Vitro
Jordan Ringer 1, Bryan Morrison 2 and Karl Kingsley 2,*
1 Department of Clinical Sciences, University of Nevada, Las Vegas—School of Dental Medicine,
1001 Shadow Lane, Las Vegas, NV 89106, USA; ringer@unlv.nevada.edu
2 Department of Biomedical Sciences and Director of Student Research, University of Nevada,
Las Vegas—School of Dental Medicine, 1001 Shadow Lane, Las Vegas, NV 89106, USA;
morrib4@unlv.nevada.edu
* Correspondence: karl.kingsley@unlv.edu; Tel.: +1-702-774-2623
Received: 9 June 2020; Accepted: 29 September 2020; Published: 1 October 2020


Abstract: Introduction: Previous studies have demonstrated that glycosaminoglycan hyaluronic acid
(HA) is capable of mediating oral tumor growth. Some clinical evidence has suggested reduced
HA expression predicts poor cancer prognosis and that HA-chemotherapy conjugates may function
synergistically to inhibit oral tumor growth. Other studies have found conflicting results that suggest
enhanced CD44-HA-mediated growth and proliferation. Due to the lack of clarity regarding HA
function, the primary goal of this study was to investigate the effects of HA using well-characterized
oral cancer cell lines. Methods: Using several commercially available oral squamous cell carcinoma
lines (and a normal non-cancerous control), 96-well growth and viability assays were conducted
using HA (alone and in combination with chemotherapeutic agents paclitaxel and PD98059). Results:
Different results were observed in each of the cell lines evaluated. HA induced small, non-significant
changes in cellular viability among each of the cell lines within a narrow range (1–8%), p = 0.207.
However, HA induced differing effects on growth, with minimal, non-significant changes among
some cell lines, such as SCC4 (+1.7%), CCL-30 (−2.8%), and SCC15 (−2.5%), p = 0.211 and more robust
inhibition among other cell lines, SCC9 (−24.4%), SCC25 (−36.6%), and CAL27 (−47.8%), p = 0.0001.
Differing effects were also observed with growth and viability under concomitant administration of
HA with PD98059 or paclitaxel. Further analysis of these data revealed strong inverse (Pearson’s)
correlations between initial baseline growth rate and responsiveness to HA administration, ranging
from R = −0.27 to R = −0.883. Conclusion: The results of this study revealed differing responses to
HA, which may be inversely correlated with intrinsic characteristics, such as the baseline growth
rate. This may suggest that the more rapidly growing cell lines are more responsive to combination
therapy with hyaluronic acid; an important finding that may provide insights into the mechanisms
responsible for these observations.
Keywords: oral cancer; hyaluronic acid; chemotherapy; paclitaxel
1. Introduction
Previous studies have demonstrated that the glycosaminoglycan hyaluronic acid (HA) is capable
of mediating oral tumor growth [1–3]. For example, recent studies of liver and pancreatic cancers have
demonstrated the role of the tumor microenvironment and HA, more specifically, to modulate
growth and progression [4,5]. This has led to an increased need to understand not only the
phenotypic-modulating potential of HA but also the interactive effects of chemotherapeutic-based
treatments involving HA co-administration [6,7].
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Some evidence from clinical studies has suggested reduced HA expression may be sufficient
to provide diagnostic and prognostic information for different types of cancer, including breast
and bladder cancers [8–10]. More recent evidence has suggested the prognostic and therapeutic
implications of HA expression may also be useful in some subsets of oral cancers [11,12]. For example,
in HPV-negative tumors, these studies revealed that high levels of stromal HA expression were, in fact,
predictors of poor clinical outcomes and reduced survival, which may be a function of interactions with
the extracellular matrix (ECM) and HA, in particular [1,11]. For example, some evidence now suggests
that degradation of HA by hyaluronidase (HAase) in some head and neck tumors may function to
create smaller fragments capable of stimulating angiogenesis—a strong negative indicator of survival
and outcome among oral cancer patients [13,14].
Despite these findings, much remains to be discovered regarding the therapeutic potential
of HA for oral cancer treatment. For example, some evidence has suggested improved clinical
outcomes for chemotherapeutic delivery with HA [15], while others have found more complicated and
conflicting results [16]. This evidence may suggest that combination therapies with HA might facilitate
chemotherapeutic potential, although much remains to be evaluated regarding which patients and
specific clinical pathophysiologic indications are most appropriate for the use and administration of
HA [17,18]. Based upon the conflicting nature of studies in this area, the primary goal of this study
was to investigate the effects of HA (alone and in combination with chemotherapeutic agents) using
well-characterized oral cancer cell lines.
2. Methods
2.1. Cell Culture
Several commercially available cell lines were obtained from the American Type Culture Collection
(ATCC; Manassas, VA, USA), which included the oral squamous cell carcinoma (SCC) lines SCC4
(CRL-1624), SCC9 (CRL-1629), SCC15 (CRL-1623), SCC25 (CRL-1628), and CAL27 (CRL-2095). The nasal
septum carcinoma line CCL-30 (RMPI-2650) and normal non-cancerous oral gingival cells HGF-1
(CRL-2014) were also obtained (Table 1).
Table 1. Verification and cross-checking of cell lines.
Cell Line Catalog Reference STR % Match Cell Type
HGF-1 CRL-2014 100% Normal oral
SCC4 CRL-1624 92% Oral squamous cell carcinoma
SCC9 CRL-1629 100% Oral squamous cell carcinoma
SCC15 CRL-1623 94% Oral squamous cell carcinoma
SCC25 CRL-1628 100% Oral squamous cell carcinoma
CAL27 CRL-2095 93% Oral squamous cell carcinoma
CCL-30 RPMI-2650 100% Nasal septum carcinoma
Available cell lines were verified and cross-checked against the International Cell Line
Authentication Committee (ICLAC) database to ensure these were not among the currently known
cross-contaminated or misidentified cell lines. Short tandem repeat (STR) profiling results for these cell
lines were compared using the eight STR loci from the ATCC database for cell line authentication.
In brief, cells were thawed and cultured according to the recommended protocol from the supplier
(ATCC). CAL27, CCL-30, and HGF-1 cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) modified to contain 10% fetal bovine serum (FBS) and 1% penicillin–streptomycin. The other
oral cancer cell lines (SCC4, SC9, SCC15, SCC25) were cultured in a 1:1 mixture of Dulbecco’s modified
Eagle’s medium and Ham’s F12 medium containing 1.2 g/L sodium bicarbonate, 2.5 mM L-glutamine,
15 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPE)S and 0.5 mM sodium pyruvate.
All cells were maintained in a humidified biosafety level-2 (BSL-2) tissue culture chamber. Experiments
were performed with cells between passages five and passage ten.
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2.2. Reagents
Hyaluronic acid (HA) was obtained from MP Biomedicals (ThermoFisher Scientific; Fair Lawn,
NJ, USA, CAS 9004-61-9) with a molecular weight (MW) of 776.651 g/mol. One chemotherapeutic
agent used in other HA-combination therapies studies of head and neck cancers [17], paclitaxel (PTX)
or Taxol, was obtained from ACROS Organics (ThermoFisher Scientific, CAS 33069-62-4) with an MW
of 853.9 g/mol. A positive control, the cellular mitogen-activated protein kinase (MAP) kinase (MEK)
inhibitor PD98059, was obtained from Invitrogen (ThermoFisher Scientific, Catalog number PHZ1164)
with an MW of 267.3 Daltons (Da).
2.3. Cellular Viability
The viability of cells was determined at the beginning and end of each experimental assay using
the trypan blue exclusion assay. In brief, a trypan blue 0.4% solution (Gibco) was added to control and
experimental cells to create a 1:1 dilution, which was incubated at room temperature. Each plate was
placed on a hemocytometer grid on a Zeiss Axiovert inverted microscope (Carl Zeiss AG, Oberkochen,
Germany). Four to six grids (1.0 mm2) were counted and averaged to determine cell number. To verify
these results, control and experimental cells were also trypsinized and diluted 1:1 with trypan blue for
viability using a BioRad TC20 automated cell counter (Bio-Rad Laboratories, Hercules, CA, USA).
2.4. Proliferation Assays
Cells were plated in 96-well tissue culture plates at a density of 1.2 × 105 cells/mL and allowed
to grow for 24, 48, and 72 h. Experimental cells were treated with 10 ng/mL of PD98059, paclitaxel
(Taxol), or both in the presence or absence of hyaluronic acid (10 ng/well), which were administered
concomitantly at the beginning of each experimental trial. Cells were subsequently fixed with 10%
formalin and stained using Gentian violet. Absorbance readings for each plate were measured using a
BioTek ELx808 (BioTek, Winooski, VT, USA) microplate reader at 595 nm to approximate cell number
and confluence.
2.5. Statistical Analysis
Differences between continuous variables (absorbance readings) were calculated using parametric
statistical analysis methods, including two-tailed Student’s t-tests and an alpha level of 0.05 to determine
significance. All experiments were performed in triplicate with n = 8 from each experimental trial for a
total n = 24 for all experimental conditions.
3. Results
Cell cultures were established for each cell line, and viability was determined to establish the
baseline before experimentation (Table 2). In brief, the viability of all cell lines ranged from 74% to
93%—with the highest viability observed among the oral squamous cell carcinomas. For example,
SCC25, SCC15, SCC9, and CAL27 exhibited viability of 93%, 91%, 89%, and 89%, respectively.
One additional oral cancer cell line (SCC4) and the nasal carcinoma (CCL-30) exhibited slightly lower
viability (82% and 74%, respectively). The normal human gingival fibroblast cell line HGF-1 exhibited
a viability of 88%.
To determine any effects of hyaluronic acid on survival, cells were plated in 96-well assays,
and average viability was measured each day over three days (Figure 1). These data revealed that no
significant differences were found in cellular viability between the control and experimental cell lines,
p = 0.207. More specifically, a few cell lines exhibited small but not significant increases in viability,
including HGF-1 (+8%), SCC9 (+3%), CCL-20 (+1%), and CAL27 (+1%), while others exhibited slight
decreases in viability (SCC4, −1%; SCC15, −3%, SCC25, −1%).
J. Funct. Biomater. 2020, 11, 72 4 of 11
Table 2. Establishment of Experimental Cell Cultures.
Cell Line Confluence Live Cell Count Viability
SCC25 (oral cancer) 1.33 × 105 cells/mL 1.23 × 105 cells/mL 93%
SCC9 (oral cancer) 7.70 × 104 cells/mL 7.01 × 104 cells/mL 91%
SCC15 (oral cancer) 8.60 × 104 cells/mL 7.65 × 104 cells/mL 89%
CAL27 (oral cancer) 1.52 × 105 cells/mL 1.35 × 105 cells/mL 89%
CCL-30 (nasal cancer) 5.68 × 104 cells/mL 4.66 × 104 cells/mL 82%
SCC4 (oral cancer) 7.17 × 104 cells/mL 5.31 × 104 cells/mL 74%
HGF-1 (normal gingiva) 4.33 × 104 cells/mL 3.81 × 104 cells/mL 88%
Ave: 86.2%
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Cell line Control (CTL)
Viability %
Experiment (HA) Statistical analysis
HGF-1 (normal gingiva) 80% 88% P=0.207
SCC4 (oral cancer) 76% 75% P=0.714
CCL-30 (nasal cancer) 81% 82% P=0.731
CAL27 (oral cancer) 88% 89% P=0.774
SCC15 (oral cancer) 92% 89% P=0.455
SCC9 (oral cancer) 88% 91% P=0.541
SCC25 (oral cancer) 93% 92% P=0.833
HA
Figure 1. Effects of hyaluronic acid (HA) on cellular viability. Comparison of control and experimental
(HYAL) assays demonstrated small, non-significant changes in cellular viability among each of the cell
lines within a narrow range over 72 h (1–8%), p = 0.207 at 72 h (24, 48 h data not depicted).
Following each measurement of viability, cells were also processed to measure growth to determine
any effects of hyaluronic acid on proliferation (Figure 2). These data revealed different effects on
growth that did not correlate with the effects on cellular viability. For example, some cells did not
exhibit any significant changes to cellular growth between the control and experimental (HA) assays,
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including SCC4 (+1.7%), CCL-30 (−2.8%), and SCC15 (−2.5%), p = 0.211. However, some oral cancer
cell lines exhibited robust reductions in cellular growth under the experimental conditions, such as
SCC9 (−24.4%), SCC25 (−36.6%), and CAL27 (−47.8%), p = 0.0001. Interestingly, the normal oral
gingiva cell line HGF-1 also demonstrated a reduction in growth (−31.8%), p = 0.002.
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Figure 2. Effects of hyaluronic acid (HA) on cellular growth. Comparison of control and experimental
(HYAL) assays demonstrated different effects, with minimal, non-significant changes among some
cell lines, such as SCC4 (+1.7%), L-30 (−2.8%), and SCC15 (−2.5%), p = 0.211 at 72 h (24, 48 h data
not depicted). More robust inhibition was observed among other cell lines, including SCC9 (−24.4%),
25 ( 36.6%), and CAL27 (−47.8%), p = 0.0001. Growth inhibition was also observed among the
normal, non-cancerous cell line HGF-1 (−31.8%), p = 0.002.
strate different eff cts in modulating the viability among various oral cancer cell lin s (Figure 3).
More specifically, the combination of HA a d PD98059 reduced cellular viability in SCC9 (−1.0%),
SCC25 (−6.9%), and CAL27 (−18.0%) cells compared with naked plastic (NP) and PD98059, while HA
and paclitaxel reduced viability in SCC25 (−8.2%), S C4 (−17.3%), and CAL27 (−4.9%) cells. However,
in other cells, the combination of HA and PD98059 increased cellular viability, such as SCC15 (+16.1%),
SCC4 (+1.8%), and CCL-30 (+11.1%), compared with NP and PD98058, while the combination of HA
and paclitaxel increased viability among SCC9 (+16.1%), SCC15 (+5.9%), and CCL-30 (+10.7%).
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Figure 3. Combined effects of hyaluronic acid (HA) and PD98059 or paclitaxel on cellular viability.
Differing effects were observed among cell lines under combination therapy with some cells exhibiting
more robust reductions in cell viability under HA and PD98059 (SCC9, SCC25, CAL27) or HA and
paclitaxel (SCC25, SCC4, CAL27). Some increases in viability were observed under HA and PD98059
with SCC15, SC 4, and CCL-30 cells, with increases also observed with HA and paclitaxel among
SCC9, SCC15, and CCL-30 cells. Note: * indicates statistical significance p < 0.05.
ifferent effects in modulating proliferation and growth among various oral c ncer cell
lines (Figure 4). More specifi ally, the combination f HA and PD98059 reduced cellu ar g owth in
SCC9 (−0.5%), SCC25 (−30.9%), and CAL27 (−29.9%) cells compared with NP and PD98059, while HA
and paclitaxe reduced viability in SCC25 (−38.9%), SCC4 (−9.7%), and CAL27 (−13.6%) cells. However,
in other cells, the combina ion of HA and PD98059 increased cellular growth, such as SCC15 (+27.7%),
4 (+26.8%), and CL-30 (+18.1%) compared with NP and PD98058, while the combination of HA
and paclitaxel increased growth among SCC9 (+10.1%), SCC15 (+4.1%), and CCL-30 (+17.0%).
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the changes in growth and viability to hyaluronic acid were assessed for any potential associations
with the baseline growth rate of each cell line (Table 3). This analysis revealed strong inverse
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Table 3. Correlation of cellular phenotype responsiveness to hyaluronic acid (HA).









CAL27 1.4 −18 −4.8 −29.9 −13.6
SCC25 1.2 −6.9 −8.2 −30.9 −38.9
SCC15 0.8 16.1 5.9 27.7 4.1
SCC9 0.76 −1 16.1 −0.5 10.1
SCC4 0.58 1.8 −17.3 16.8 −9.7
CCL-30 0.55 11.1 10.7 18.11 17
Correlation R = −0.80026 R = −0.27006 R = −0.8831 R = −0.68196
4. Discussion
The primary goal of this study was to investigate the effects of hyaluronic (alone and in combination
with chemotherapeutic agents) using well-characterized oral cancer cell lines to determine any potential
effects on cellular phenotypes, such as growth and viability. The results of this study revealed differing
responses to both phenotypes, which may be inversely correlated with intrinsic characteristics, such as
the baseline growth rate. This may suggest that the more rapidly growing cell lines are more responsive
to combination therapy with hyaluronic acid; an important finding that may provide insights into the
mechanisms responsible for these observations.
For example, one recent study demonstrated synergistic effects similar to those observed in this
study with combination cisplatin–hyaluronic acid treatment in advanced metastatic ovarian cancer [19].
Another study also found that combination therapy involving hyaluronic acid exhibited synergistic
and enhanced anti-tumor effects among aggressive breast cancers [20]. These data may suggest the
results of this study may be consistent with other studies of combination therapies using hyaluronic
acid with other aggressive and metastatic tumors.
In addition, these results may suggest that the extracellular matrix (ECM)-mediated responses
may, in fact, play significant roles in tumor responsiveness to chemotherapy [21,22]. This may be
due to the expression of hyaluronidases and matrix metalloproteinases, such as MMP-2 and MMP-9,
among advanced and metastatic cancers that cleave ECM (including hyaluronic acid) and reduce
cell-ECM contacts, adhesion, and the associated intracellular signaling [23,24]. In addition, this may
also suggest that expression of MMP-2 and MMP-9 may serve as a biomarker or indicator to determine
if combination therapy, including hyaluronic acid, may be indicated—although more research will be
needed to make these determinations [25].
Although some previous studies have suggested that high expression of HA in both tumor and
stromal cells from resected oral cancer patients may correlate with poor prognosis [11,14], these studies
also confirm previous observations that proteolytic cleavage of HA by hyaluronidases and matrix
metalloproteinases (MMPs) may trigger the invasion and metastasis via the receptor for hyaluronan
(HA)-mediated motility (RHAMM) CD44 [18,25]. In fact, some evidence now suggests that CD44 acts
as a receptor for proteolytically-modified HA and may be responsible for the modulation of intracellular
signaling associated with increased proliferation and invasive capacity [17,26,27]. However, because
the production of proteolytic enzymes with their cognate targets may be tightly regulated within
these tumors, administration of intact, exogenous HA and the delivery of chemotherapeutic agents
conjugated with HA has been sufficient in clinical studies to improve patient outcomes and reduce
metastatic phenotypes in many cancer types [17,18,28–30].
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5. Conclusions
Although much remains to be elucidated, these findings suggest that hyaluronic acid may, in fact,
exert different effects in oral squamous cell carcinomas. Elucidation of the factors that more accurately
determine oral cancer responsiveness, such as CD44, MMP-2, MMP-9, and hyaluronidase expression,
may be needed to allow oral healthcare researchers and clinicians to more accurately assess and treat oral
cancers with the most efficient and effective means of treatment that may include combination therapy
with hyaluronic acid. Because this study revealed differential responses, which may be inversely
correlated with intrinsic characteristics, such as baseline growth rate, the analysis and identification
of those factors that correlate with responsiveness to combination therapy with hyaluronic acid may
provide important insights into the mechanisms responsible for these observations.
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